Login / Signup

The Benefits of Adjuvant Trastuzumab for HER-2-Positive Salivary Gland Cancers.

Glenn J HannaJi Eun BaeJochen H LorchRobert I HaddadVickie Y JoJonathan D SchoenfeldDanielle N MargalitRoy B TishlerLaura A GoguenDonald J AnninoNicole G Chau
Published in: The oncologist (2020)
Results of this study showed an improved disease-free and overall survival in patients treated with adjuvant trastuzumab for high-risk salivary gland cancers with strong HER-2/neu staining intensity. Following recurrence or metastatic spread, sequential HER-2, and androgen-directed therapies may benefit certain patients with salivary gland cancer.
Keyphrases
  • early stage
  • epidermal growth factor receptor
  • free survival
  • small cell lung cancer
  • squamous cell carcinoma
  • papillary thyroid
  • metastatic breast cancer
  • childhood cancer
  • high intensity
  • squamous cell
  • flow cytometry